

Special Issue

Searching for Small Molecules as Antimicrobials

Message from the Guest Editor

Antimicrobial resistance is a growing problem in the treatment of infectious diseases, as it restricts antimicrobials' efficacy in nearly every infection. However, the population-level consumption of these drugs has not decreased, due to their undisputed usefulness. Currently, the treatment and prevention of COVID-19, caused by novel coronavirus SARS-CoV-2, involves the use of antimicrobials. Therefore, there is an urgent need for the development of new, effective, broad-spectrum antimicrobial agents. Small molecules have gained great attention in the past two decades because of their remarkable advantages, such as low weight, ease of synthesis, low cost, and flexibility. They are widely used as tools for novel drugs; therefore, small molecules and small-molecule-containing drugs are certain to play an increasingly important role in medicinal chemistry. This Special Issue seeks manuscript submissions that can improve the existing knowledge about small molecules as antimicrobial agents.

Guest Editor

Dr. Alessia Catalano

Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 70126 Bari, Italy

Deadline for manuscript submissions

closed (31 March 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/83337

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)